Targeting Signal Transducer and Activator of Transcription Signaling Pathway in Leukemias
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Signal transducer and activator of transcription (STAT) proteins comprise a seven-member family of latent cytoplasmic transcription factors that are activated through tyrosine phosphorylation by a variety of cytokines and growth factors. Aberrant activation of STATs accompanies malignant cellular transformation with resultant leukemogenesis. Constitutive activation of STATs has been demonstrated in various leukemias. A better understanding of the mechanisms of dysregulation of the STAT pathway and understanding of the cause and effect relationship in leukemogenesis may serve as a basis for designing novel therapeutic strategies directed against STATs. Mechanisms of STAT activation, the potential role of STAT signaling in leukemogenesis, and recent advances in drug discovery targeting the STAT pathway are the focus of this review.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Darnell, J. E. (1997) · Science · doi:10.1126/science.277.5332.1630 · Cited by 3,979
Bromberg, J. F., Wrzeszczynska, M. H., Devgan, G., Zhao, Y., Pestell, R. G., Albanese, C., & Darnell, J. E. (1999) · Cell · doi:10.1016/s0092-8674(00)81959-5 · Cited by 2,790
The STATs of cancer — new molecular targets come of age
Yu, H., & Jove, R. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1275 · Cited by 2,278 · cited 1×
“Dysregulation of the STAT signaling pathway plays a role in oncogenesis and leukemogenesis.(31,32) As a proof of concept, inhibition of aberrant STAT activity has been repeatedly shown to result in arrest of tumor development and apoptosis.”
BackgroundConstitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis
Niu, G., Wright, K. L., Huang, M., Song, L., Haura, E., Turkson, J., Zhang, S., Wang, T., Sinibaldi, D., Coppola, D., et al. (2002) · Oncogene · doi:10.1038/sj.onc.1205260 · Cited by 1,207 · cited 1×
“Finally, a particularly intriguing role for constitutive STAT3 activity in the upregulation of vascular endothelial growth factor expression and tumor angiogenesis was demonstrated.(45,50) In summary, STAT3 seems to be the central transcription factor for many signaling pathways.”
BackgroundEpling-Burnette, P. K., Liu, J. H., Catlett-Falcone, R., Turkson, J., Oshiro, M., Kothapalli, R., Li, Y., Wang, J.-M., Yang-Yen, H.-F., Karras, J., et al. (2001) · Journal of Clinical Investigation · doi:10.1172/jci9940 · Cited by 633 · cited 2×
“Inhibition of upstream tyrosine kinases, such as Janus family tyrosine kinase (JAK), breakpoint cluster region-abelson tyrosine kinase, FMS-related tyrosine kinase 3, and sarcoma (Schmidt-Ruppin A-2) viral oncogene homolog (avian), with resultant downregulation of STATs has proven to be the most effective STAT-targeti…”
BackgroundStat3 Activation Is Required for Cellular Transformation by v- src
Bromberg, J. F., Horvath, C. M., Besser, D., Lathem, W. W., & Darnell, J. E. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.5.2553 · Cited by 614
Identification of a Nuclear Stat1 Protein Tyrosine Phosphatase
ten Hoeve, J., de Jesus Ibarra-Sanchez, M., Fu, Y., Zhu, W., Tremblay, M., David, M., & Shuai, K. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.16.5662-5668.2002 · Cited by 507 · cited 1×
“STAT activation with nuclear accumulation terminates within minutes.(29) STATs dephosphorylated by nuclear phosphatases, such as TC45, are actively exported back to the cytoplasm by binding to chromosome region maintenance 1 (CRM1; also called exportin-1) protein.”
BackgroundReich, N. C., & Liu, L. (2006) · Nature Reviews Immunology · doi:10.1038/nri1885 · Cited by 376
STAT3 nuclear import is independent of tyrosine phosphorylation and mediated by importin-α3
Liu, L., McBride, K. M., & Reich, N. C. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501643102 · Cited by 348 · cited 5×
“A better understanding of the mechanisms of dysregulation of the STAT pathway and understanding of the cause and effect relationship in leukemogenesis may serve as a basis for designing novel therapeutic strategies directed against STATs.”
BackgroundInfluentialTurkson, J., Zhang, S., Palmer, J., Kay, H., Stanko, J., Mora, L. B., Sebti, S., Yu, H., & Jove, R. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.1533.3.12 · Cited by 188 · cited 1×
“(L) Novel platinum (IV) compounds directly bind to STAT molecule and block DNA-binding activity.(108,109) P, phosphorus; Onco-PTK, oncogenic PTK.”
BackgroundReal time analysis of STAT3 nucleocytoplasmic shuttling
Pranada, A. L., Metz, S., Herrmann, A., Heinrich, P. C., & Müller-Newen, G. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m312530200 · Cited by 140
Nucleocytoplasmic shuttling of persistently activated STAT3
Herrmann, A., Vogt, M., Mönnigmann, M., Clahsen, T., Sommer, U., Haan, S., Poli, V., Heinrich, P. C., & Müller-Newen, G. (2007) · Journal of Cell Science · doi:10.1242/jcs.03482 · Cited by 94 · cited 3×
“Inhibition of STAT Nucleocytoplasmic Shuttling Targeting STAT nuclear traffic is another promising strategy of developing cancer drugs.(28) This is especially important for STAT3 because of its prominent nuclear presence independent of its phosphorylation.”
BackgroundBiethahn, S., Alves, F., Wilde, S., Hiddemann, W., & Spiekermann, K. (1999) · Experimental Hematology · doi:10.1016/s0301-472x(99)00017-x · Cited by 74 · cited 1×
“STAT activation in leukemic cell lines(51,52) and blasts from AML and acute lymphoblastic leukemia (ALL) patients has been demonstrated (Table 3).(49,51,53-59) STAT3 activity is most prevalent in AML, whereas STAT5 activity is more common in ALL.”
BackgroundHuang, Y., Qiu, J., Dong, S., Redell, M. S., Poli, V., Mancini, M. A., & Tweardy, D. J. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m704548200 · Cited by 65
Cited by
Targeting the IL-6/JAK/STAT3 signalling axis in cancer
Johnson, D. E., O'Keefe, R. A., & Grandis, J. R. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.8 · Cited by 3,110
Therapeutic modulators of STAT signalling for human diseases
Miklossy, G., Hilliard, T. S., & Turkson, J. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4088 · Cited by 413
The potential and controversy of targeting STAT family members in cancer
Verhoeven, Y., Tilborghs, S., Jacobs, J., De Waele, J., Quatannens, D., Deben, C., Prenen, H., Pauwels, P., Trinh, X. B., Wouters, A., et al. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.10.002 · Cited by 409
Brault, L., Gasser, C., Bracher, F., Huber, K., Knapp, S., & Schwaller, J. (2010) · Haematologica · doi:10.3324/haematol.2009.017079 · Cited by 368
Bharadwaj, U., Kasembeli, M. M., Robinson, P., & Tweardy, D. J. (2020) · Pharmacological Reviews · doi:10.1124/pr.119.018440 · Cited by 314
“SUMO, another ubiquitin-related molecule that conjugates to STAT3 at lysine residue K451 in a process called SUMOylation, appears to negatively regulate the JAK/ STAT3 pathway (Benekli et al., 2009) by promoting its binding to the phosphatase TC45, through the SUMOinteracting motif of TC45, leading to pY-STAT3 dephosp…”
Background
Metadata
- Authors
- Benekli, M., Baumann, H., & Wetzler, M.
- Venue
- Journal of Clinical Oncology
- Published
- 2009-09-10
- Volume
- 27
- Issue
- 26
- Pages
- 4422-4432
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2019308110
- Cited by
- 140
- References
- 14
- FWCI
- 4.48
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.